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Introduction {#sec1}
============

A crucial step in the polarization of metazoan cells is the localization of conserved sets of polarity effectors, known as the partitioning-defective or PAR proteins, to discrete membrane-associated cortical domains. Regulation of PAR protein distribution is essential for the localized activation of signaling pathways that coordinate many aspects of embryonic development, including asymmetric cell division, epithelial organization, and embryo axis establishment ([@bib29], [@bib75]). Although the precise details vary between systems, in most cases the conserved PDZ domain proteins PAR-3 and PAR-6, the small guanosine triphosphatase (GTPase) CDC-42 and atypical protein kinase C (aPKC) act together to establish polarity on one side of the cell and drive asymmetry of a range of downstream pathways (reviewed in [@bib26], [@bib53], [@bib76], [@bib84]).

In *Caenorhabditis elegans*, PAR-3, PAR-6, CDC-42, and the aPKC ortholog, PKC-3, play an essential role in polarizing the one-cell embryo or zygote by defining an anterior domain and hence are referred to as anterior PARs or aPARs ([Figures 1](#fig1){ref-type="fig"}A--1C). An opposing set of posterior PARs or pPARs, consisting of PAR-1, PAR-2, LGL-1, and the CDC-42 GAP, CHIN-1, form a complementary domain at the posterior. Together, aPARs and pPARs define the anterior-posterior axis of the zygote and orchestrate an asymmetric division that restricts germline determinants to the posterior daughter cell ([@bib6], [@bib11], [@bib23], [@bib30], [@bib33], [@bib36], [@bib44], [@bib47], [@bib77], [@bib79]).Figure 1PKC-3 Kinase Inhibition Leads to Symmetric Division and Loss of Asymmetry of Downstream Polarity Markers(A--C) Model for symmetry breaking by the PAR system in *C. elegans*. aPARs (red) initially occupy the membrane and pPARs (blue) are cytoplasmic (A, Meiosis II). A cue (purple) from the centrosome pair (black spheres) segregates aPARs into the anterior and promotes formation of a posterior PAR domain at the opposite pole (A, Establishment). PAR domains are then stable until cytokinesis (A, Maintenance) and drive polarization of cytoplasmic factors such as MEX-5/6 (green) and P granules (orange), which ensure the daughter cells acquire distinct fates (A, Two-cell). (B) Symmetry breaking can occur in two ways: (i) segregation of aPARs by cortical actomyosin flow (advection); and (ii) posterior PAR-2 loading. (C) A complex network of physical and regulatory interactions links the PAR proteins. Membrane binding (gray lines), physical interactions (black lines), as well as positive (→) and negative (⊥) feedback, are shown. Where links are indirect or unknown, dashed lines are used. Both CDC-42 and PAR-3 are required for stable membrane association of PAR-6/PKC-3. PAR-6 and PKC-3 depend on each other for membrane association. PAR-2, LGL-1, and presumably CHIN-1, are able to load onto the membrane independently. PAR-1 also binds membrane but requires PAR-2 to reach maximal concentrations. PKC-3 phosphorylates PAR-1, PAR-2, and LGL-1 and displaces them from the membrane. Exclusion of CHIN-1 from the anterior is dependent on PKC-3, but whether it is a direct target of PKC-3 is unknown. Together, PAR-1, via phosphorylation of PAR-3, and CHIN-1, by suppressing activated CDC-42, prevent invasion of the posterior domain by aPARs. PAR-3 and PAR-2 have been proposed to undergo oligomerization, which is thought to enhance their membrane association (noted by circular arrows). See recent reviews ([@bib26], [@bib37], [@bib58]) for more information.(D) Midsection confocal images of fixed zygotes stained for PAR-2 at polarity maintenance and two-cell stage comparing wild-type, *pkc-3*(*ts*), and *pkc-3*(*RNAi*) conditions.(E) Midsection fluorescent images of mCherry:PAR-2-expressing zygotes at maintenance and two-cell stage in DMSO (control), CRT90-treated, and *pkc-3*(*RNAi*).(F) Midsection (PAR-1, LGL-1, PIE-1, MEX-5) or cortical (CHIN-1) fluorescent images of maintenance-phase zygotes expressing markers to various downstream polarity markers in DMSO (control), CRT90-treated, and *pkc-3*(*RNAi*). Asymmetry in (D) to (F) is quantified by the asymmetry index, with one being normal asymmetry and zero, no asymmetry (ASI, normalized to DMSO/WT controls).^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001. Scale bars, 10 μm. See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}; [Movie S1](#mmc2){ref-type="supplementary-material"}.

Polarization is triggered by the sperm-donated centrosome via two semi-redundant pathways ([Figures 1](#fig1){ref-type="fig"}A and 1B). First, the centrosome induces actomyosin cortical flow away from the newly defined posterior pole, which transports membrane-associated aPAR proteins into the anterior ([@bib15], [@bib28], [@bib52], [@bib61]). Second, centrosomal microtubules promote local loading of PAR-2 in the posterior. PAR-2 then recruits PAR-1, which drives posterior exclusion of aPARs through phosphorylation of PAR-3 ([@bib11], [@bib34], [@bib60]). Following this "establishment phase," the zygote enters a "maintenance phase" during which mutual antagonism between anterior and posterior PARs ensures their continued asymmetric localizations ([@bib11], [@bib16], [@bib23], [@bib33], [@bib77], [@bib79]).

Anterior PAR protein function is mediated through the kinase activity of PKC-3, which can phosphorylate PAR-1, PAR-2, and LGL-1 and drive their dissociation from the membrane ([@bib6], [@bib34], [@bib36], [@bib39], [@bib60]). PAR-3, PAR-6, and CDC-42 are all required for proper PKC-3 membrane localization ([@bib30], [@bib44], [@bib71], [@bib77]). Consequently, loss of any of these four proteins results in identical zygote polarity phenotypes: posterior PAR proteins are found uniformly on the embryo membrane and the first cell division is symmetric, leading to cell fate defects and embryo lethality ([@bib23], [@bib44], [@bib77], [@bib79]).

This similarity of aPAR mutant phenotypes, their co-segregation within the anterior domain, and their ability to interact with one another in a wide range of systems ([@bib40], [@bib41], [@bib51], [@bib65]) has led to consideration of an effective aPAR unit comprising PAR-3, PAR-6, PKC-3, and CDC-42. However, work across a range of cell types suggests that such minimalism belies significant complexity in the regulation of aPAR localization and function, which we are only beginning to decipher.

For example, in epithelia, PAR-3 and aPKC localize to distinct regions of the apical domain: PAR-3 is primarily junctional, while PAR-6 and aPKC are more apical and, together with CDC-42 and Crumbs, exclude PAR-1 and LGL from the apical domain ([@bib10], [@bib35], [@bib57], [@bib81], [@bib82]).

In the *C. elegans* zygote, two modes of aPAR membrane association have been proposed: one associated with PAR-3 and independent of CDC-42, and one dependent on CDC-42 but not associated with PAR-3. Supporting this hypothesis, PAR-6 and PKC-3 only partially co-localize with PAR-3 in wild-type embryos, but co-localize strongly when CDC-42 is depleted ([@bib8], [@bib38], [@bib77]). However, it remains unclear whether these observations reflect the existence of discrete functional modules and, if so, what their respective functions are.

A primary role of the aPAR network is to restrict PKC-3 kinase activity to the anterior domain. However, because localization, function, and regulation of PKC-3 are tightly coupled, parsing their individual contributions is difficult using traditional RNAi and knockout studies. Consequently, despite the central role of PKC-3 in polarity, we lack insight into how the individual contributions by PAR-3, PAR-6, CDC-42, and PKC-3 itself combine to ensure PKC-3 is activated only within the anterior domain. To address these questions, we require tools to independently modulate the localization and function of aPAR proteins.

Here we describe methods to independently manipulate PKC-3 activity and localization, which we use to investigate how PKC-3 kinase activity regulates organization of the aPAR network, and how PKC-3 activity is modulated by other network members. We find that localized PKC-3 kinase activity is linked to dynamic cycling of PAR-6/PKC-3 between two functionally distinct aPAR assemblies: (1) a PAR-3-dependent assembly that is associated with clusters and efficiently responds to polarizing cues, but in which PKC-3 activity is inhibited, and (2) a more diffuse CDC-42-dependent assembly that is less able to respond to polarizing cues but contains active PKC-3 and is responsible for posterior PAR protein exclusion. We propose that the dynamic exchange of PAR-6/PKC-3 between these two assemblies allows the PAR network to efficiently translate symmetry-breaking cues into an asymmetric homogeneous domain of PKC-3 activity.

Results {#sec2}
=======

Acute Inhibition of PKC-3 Function Leads to Loss of Asymmetric Division {#sec2.1}
-----------------------------------------------------------------------

We took two approaches to inhibit PKC-3 kinase activity. First, we examined a previously identified temperature-sensitive allele of *pkc-3*, *ne4246* ([@bib25]), which alters a conserved Asp residue (D386V) close to the active site. Strains carrying *pkc-3*(*ne4246*) are subsequently referred to as *pkc-3*(*ts*)*.* Consistent with loss of PKC-3 function, in *pkc-3*(*ts*) zygotes at the restrictive temperature (25°C), PAR-2 is not restricted to the posterior membrane and is partitioned symmetrically into the two blastomeres at the first cell division ([Figure 1](#fig1){ref-type="fig"}D). Loss of asymmetry was quantified by the asymmetry index (ASI) (see [STAR Methods](#sec4){ref-type="sec"}), which measures the asymmetry of a feature, e.g., PAR-2 membrane intensity, relative to wild-type on a scale from zero (no asymmetry) to 1 (normal asymmetry) ([Figure 1](#fig1){ref-type="fig"}D and [Movie S1](#mmc2){ref-type="supplementary-material"}). Results below and in [Figure S1](#mmc1){ref-type="supplementary-material"} indicate that loss of asymmetry in *pkc-3*(*ts*) zygotes is due to loss of PKC-3 activity rather than degradation.

In parallel, we examined PKC-3 inhibitors in permeable, *perm-1*(*RNAi*) embryos ([@bib13]) to identify compounds that yielded a PKC-3 deficient polarity phenotype. One compound, CRT0103390 (CRT90), a derivative of CRT0066854 ([Figures S2](#mmc1){ref-type="supplementary-material"}A--S2C) ([@bib45], [@bib21]) resulted in embryos that progressed normally through the cell cycle but showed loss of PAR-2 asymmetry and divided symmetrically ([Figure 1](#fig1){ref-type="fig"}E and [Movie S1](#mmc2){ref-type="supplementary-material"}). CRT90 embryos exhibited other common phenotypes associated with *pkc-3*(*RNAi*) and *pkc-3*(*ts*), including simultaneous division of the two daughter cells and ectopic spindle rotation in the anterior daughter cell, leading to a chain-like arrangement of cells in the 4-cell embryo (data not shown). As expected for an inhibitor of PKC-3 activity, CRT90 treatment caused loss of asymmetry in other posterior PAR proteins (PAR-1, LGL-1, and CHIN-1) as well as the loss of cytoplasmic asymmetry in the cell fate determinants PIE-1 and MEX-5 ([Figure 1](#fig1){ref-type="fig"}F).

PKC-3 Inhibition Yields Distinct Phenotypes from PKC-3 Depletion {#sec2.2}
----------------------------------------------------------------

We next investigated the distributions of the anterior PAR proteins when PKC-3 activity was inhibited, and compared these to those observed when PKC-3 was depleted by RNAi. Normally, PAR-3, PAR-6, and PKC-3 are efficiently segregated into the anterior during the polarity establishment phase and remain asymmetric until cytokinesis ([Figures 1](#fig1){ref-type="fig"}A and [2](#fig2){ref-type="fig"}A--2F) ([@bib16]). When PKC-3 is depleted by RNAi of *pkc-3*, PAR-6 fails to localize to the membrane ([Figure 2](#fig2){ref-type="fig"}A) ([@bib38]). By contrast, PAR-3 remains membrane associated and segregates into the anterior, but this population is generally reduced compared to wild-type and is lost as the cell proceeds through mitosis ([Figure 2](#fig2){ref-type="fig"}E) ([@bib77]).Figure 2Membrane Localization of PAR-6/PKC-3 Is Decoupled from PAR-3 when PKC-3 Is Inactive(A--F) Representative midsection confocal images of live and fixed zygotes at establishment and maintenance phase comparing control (DMSO, wild-type), *pkc-3*(*RNAi*), and PKC-3-inhibited (CRT90, *pkc-3*(*ts*)) conditions. PAR-6 (A and B) and PKC-3 (C and D) show loss of asymmetric membrane staining in PKC-3-inhibited zygotes at both establishment and maintenance phase (posterior localization indicated by white arrowheads). In *pkc-3*(*RNAi*), PAR-6 is absent from the membrane at all times. PAR-3 (E and F) still polarizes in PKC-3-inhibited zygotes, but becomes weaker and less asymmetric during maintenance phase. Note that (B), (D), and (F) show the same wild-type and TS zygotes with the PAR-3 boundary position in TS indicated (red arrowheads) to allow comparison: PAR-6 and PKC-3 are clearly visible at the posterior membrane (white arrowheads), while PAR-3 is undetectable, as in wild-type. Bright foci in (D) are non-specific centrosome staining.(G and H) Normalized ASI measurements for late establishment phase datasets represented in (A) to (F). ASI is normalized to control (wild-type \[WT\] or DMSO) for each protein.(I and J) Anterior to posterior membrane distributions of PAR-3 (red) and PKC-3 (black) in wild-type (I) and *pkc-3*(*ts*) (J) embryos. Arrows highlight the posterior extension of PKC-3 relative to PAR-3. Mean ± SD is shown.(K) Close-up view of the boundary region showing PAR-3 (top) and PKC-3 (bottom) for one representative zygote for wild-type (WT) and *pkc-3*(*ts*) backgrounds as indicated. Dashed rectangular selection denotes regions where PKC-3 is present in absence of PAR-3.(L) PKC-3 to PAR-3 ASI ratio for wild-type (WT) and *pkc-3*(*ts*).(M) Dual labeling of PAR-2 and PKC-3 in live, CRT90-treated zygotes (top) and fixed, *pkc-3*(*ts*) embryos (bottom) reveal overlap of aPAR and pPAR proteins.^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001. ns, not significant. Scale bars, 10 μm. See also [Figures S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}; [Movie S2](#mmc3){ref-type="supplementary-material"}.

Unlike *pkc-3*(*RNAi*), when PKC-3 is inhibited by the D386V mutation or CRT90, PAR-6 and PKC-3 remain membrane associated, fail to segregate efficiently to the anterior, and a significant pool of both proteins remains localized at the posterior pole resulting in a loss of asymmetry relative to controls ([Figures 2](#fig2){ref-type="fig"}A--2D, 2G, and 2H; [Movie S2](#mmc3){ref-type="supplementary-material"}). In contrast to PAR-6 and PKC-3, PAR-3 still segregates into the anterior during the establishment phase in PKC-3-inhibited zygotes ([Figures 2](#fig2){ref-type="fig"}E and 2F, Establishment). The domain is typically somewhat enlarged relative to wild-type zygotes, but PAR-3 asymmetry remains high and PAR-3 is absent from the posterior pole ([Figures 2](#fig2){ref-type="fig"}G and 2H). Following the establishment phase, PAR-3 levels at the membrane decline and become more symmetric ([Figures 2](#fig2){ref-type="fig"}E and 2F, Maintenance).

The distinct response of PAR-3 versus PAR-6 and PKC-3 is particularly clear in the quantification of dual-labeled fixed zygotes. In wild-type zygotes, the boundaries of the PAR-3 and PKC-3 domains are positioned similarly at the center of the zygote, although the PKC-3 domain extends a few microns further into the posterior ([Figures 2](#fig2){ref-type="fig"}I and 2K, WT). By contrast, in PKC-3-inhibited embryos, PKC-3 extends significantly further into the posterior compared with PAR-3, a condition we refer to as "decoupled" ([Figures 2](#fig2){ref-type="fig"}J--2L, TS). Consistent with this decoupling, upon PKC-3-inhibition we observe a decrease in co-localization between PAR-3 and PAR-6 at the membrane/cortex, even in the anterior domain where these PAR proteins overlap ([Figure S3](#mmc1){ref-type="supplementary-material"}). Thus, we conclude that PKC-3 is required for the normally tight coupling between PAR-6/PKC-3 and PAR-3 during symmetry breaking.

These results point to an unappreciated complexity in the assembly and regulation of the PAR proteins at the cell membrane:

First, the loss of membrane-associated PAR-6 in PKC-3-depleted zygotes, but not in PKC-3-inhibited zygotes ([Figure 2](#fig2){ref-type="fig"}A), shows that disruption of PKC-3 activity or the resulting invasion of pPARs into the anterior ([Figures 1](#fig1){ref-type="fig"}D--1F) do not account for loss of PAR-6 membrane association. Rather, there appears to be a requirement for PKC-3 protein itself to target and stabilize PAR-6 at the membrane. Consistent with this interpretation, mutations in *par-2* and *par-1* fail to rescue PAR-6 membrane localization in *pkc-3*(*RNAi*) zygotes ([Figure S4](#mmc1){ref-type="supplementary-material"}).

Second, in PKC-3-inhibited zygotes, anterior and posterior PAR protein distributions on the membrane overlap ([Figure 2](#fig2){ref-type="fig"}M). Posterior PAR proteins are thought to directly antagonize the ability of anterior PAR proteins to associate with the membrane, yet in these zygotes aPARs appear resistant to pPAR antagonism. PKC-3 inhibition could conceivably affect the activity of posterior PARs. However, we found that PAR-1 kinase activity, as measured by MEX-5 mobility ([@bib32]), appears normal in PKC-3-inhibited zygotes ([Figures S2](#mmc1){ref-type="supplementary-material"}D--S2F). Thus, PKC-3 activity appears necessary to render anterior PARs sensitive to the antagonistic effects of posterior PARs, challenging the simple paradigm of mutual antagonism, which would predict pPAR dominance.

Finally, decoupling of PAR-6/PKC-3 from PAR-3 localization in PKC-3-inhibited zygotes during symmetry breaking suggests that PKC-3 drives formation of distinct PAR complexes or assemblies during polarity establishment in the *C. elegans* zygote. Contrary to what has been observed in *Drosophila* epithelia, where aPKC activity promotes decoupling of PAR-3 from PAR-6/aPKC and their targeting to distinct sites ([@bib57]), here we observe the opposite: PKC-3 kinase activity is implicated in coupling the behaviors of PAR-3 and PAR-6/PKC-3, allowing their coordinated segregation during symmetry breaking.

PKC-3 Inhibition Promotes PAR-3-Independent Formation of CDC-42-Dependent PAR-6/PKC-3 Assemblies {#sec2.3}
------------------------------------------------------------------------------------------------

If PKC-3 inhibition favors formation or trapping of a distinct functional assembly, we reasoned that it might affect the normal dependencies of PAR-6 and PKC-3 on PAR-3 and CDC-42. PKC-3 and PAR-6 normally require both PAR-3 and CDC-42 to localize stably to the membrane ([@bib8], [@bib69]). The dependency on PAR-3 is stronger: PKC-3 and PAR-6 fail to localize to the membrane in PAR-3-depleted zygotes (*par-3*(*RNAi*) in [Figures 3](#fig3){ref-type="fig"}A--3F) ([@bib77]). By contrast, in CDC-42-depleted zygotes, PKC-3 and PAR-6 initially localize to the membrane and segregate to the anterior, but their membrane localization is gradually lost during the maintenance phase, becoming weaker and more uniform as zygotes approach cytokinesis (*cdc-42*(*RNAi*) [Figures 3](#fig3){ref-type="fig"}A--3F and [Movie S4](#mmc5){ref-type="supplementary-material"})([@bib8], [@bib30], [@bib59], [@bib69], [@bib71]). Importantly, depletion of PAR-1 or PAR-2, which invade the anterior in the absence of PAR-3 or CDC-42 ([@bib23], [@bib30], [@bib44], [@bib71]), fails to rescue PAR-6 membrane localization in these conditions ([Figure S4](#mmc1){ref-type="supplementary-material"}). Thus, both PAR-3 and CDC-42 are directly required to promote membrane association of PAR-6 and PKC-3.Figure 3PKC-3 Inhibition Promotes PAR-3-Independent Formation of CDC-42-Dependent PAR-6/PKC-3 Assemblies(A--C) Representative midsection confocal images of live embryos at maintenance phase showing GFP::PKC-3 (A) or PAR-6::GFP (B and C) of DMSO, CRT90-treated, and *pkc-3*(*ts*) zygotes subject to RNAi as indicated.(D) Quantification of rescue for datasets represented in (A) to (C), normalized to membrane signal in control RNAi and CRT90-treated/*pkc-3*(*ts*) zygotes for each dataset.(E) Representative midsection confocal images of wild-type and *pkc-3*(*ts*) zygotes during polarity establishment subject to RNAi as indicated and immunostained for PKC-3.(F) Quantification of rescue as measured by anterior domain cortical intensity of PKC-3 for datasets represented in (E). For each zygote, anterior PKC-3 cortical intensity is divided by cytoplasmic intensity. Values greater than 1 indicate presence at the membrane. Mean ± 95% confidence interval (CI) (N) is shown. See [STAR Methods](#sec4){ref-type="sec"} for further details.(G) Representative midsection confocal images during polarity establishment of wild-type and *pkc-3*(*ts*) embryos upon *cgef-1*(*RNAi*), stained for PKC-3. Scatterplot representing the anterior domain cortical intensity of PKC-3 as in (F) in *cgef-1*(*RNAi*) and *pkc-3*(*ts*);*cgef-1*(*RNAi*). Mean ± 95% CI (N) is shown.^∗∗^p \< 0.01, ^∗∗∗∗^p \< 0.0001. ns, not significant. Scale bars, 10 μm. See also [Figure S5](#mmc1){ref-type="supplementary-material"}; [Movies S3](#mmc4){ref-type="supplementary-material"} and [S4](#mmc5){ref-type="supplementary-material"}.

We find that under conditions of PKC-3 inhibition (D386V or CRT90), PKC-3 and PAR-6 no longer depend on PAR-3 to localize to the membrane ([Figures 3](#fig3){ref-type="fig"}A--3F and [S5](#mmc1){ref-type="supplementary-material"}A; [Movies S3](#mmc4){ref-type="supplementary-material"} and [S4](#mmc5){ref-type="supplementary-material"}). The degree of localization varies between the two methods of PKC-3 inhibition, possibly reflecting differences in the mechanism or timing/kinetics of kinase inhibition. By contrast, CDC-42 is still required for PKC-3 and PAR-6 membrane localization in PKC-3-inhibited zygotes ([Figures 3](#fig3){ref-type="fig"}A--3F, [S5](#mmc1){ref-type="supplementary-material"}A, and S5B; [Movie S4](#mmc5){ref-type="supplementary-material"}), indicating that CDC-42 is still required for PAR-6/PKC-3 membrane targeting even when PKC-3 is inhibited. Consistent with previous work showing that PAR-6/aPKC are typically associated with an active, guanosine triphosphate (GTP)-bound form of CDC-42 ([@bib4], [@bib30], [@bib41], [@bib51], [@bib65]), we found that decreasing CDC-42/GTP by depletion of the CDC-42 GEF, CGEF-1, reduces membrane association of PAR-6/PKC-3 in *pkc-3*(*ts*) embryos compared with wild-type, while leaving PAR-3 levels unchanged ([Figures 3](#fig3){ref-type="fig"}G and [S5](#mmc1){ref-type="supplementary-material"}A--S5E). Finally, PKC-3 remains dependent on PAR-6 in PKC-3-inhibited embryos, consistent with PAR-6 being required to mediate the interactions of the PAR-6/PKC-3 heterodimer with PAR-3 and/or CDC-42 ([Figures 3](#fig3){ref-type="fig"}A and 3D--3F; [Movie S4](#mmc5){ref-type="supplementary-material"}) ([@bib41], [@bib65]), as well as our general findings that PKC-3 and PAR-6 respond similarly in all assays described.

Thus, inhibition of PKC-3 activity allows PKC-3 to bypass its normal requirement on PAR-3 to load onto the membrane and form stable membrane-associated CDC-42/GTP-dependent complexes. We postulate that it is this dependency on PAR-3, enforced by PKC-3 kinase activity, that ensures the coupled distributions of PKC-3 and PAR-3 in the embryo.

Segregation of Anterior PAR Proteins Is Associated with PAR-3-Dependent Clustering at the Membrane {#sec2.4}
--------------------------------------------------------------------------------------------------

So far, we have shown that inhibition of PKC-3 kinase activity promotes CDC-42-dependent assemblies, and in so doing prevents PKC-3 and PAR-6 from segregating efficiently with PAR-3 into the anterior during symmetry breaking. Previous work has shown that the efficient segregation of anterior PAR proteins is due to advective transport by anteriorly-directed actomyosin cortical flow ([@bib15], [@bib28], [@bib61]). Because PAR-3 continues to be segregated efficiently in PKC-3-inhibited zygotes, we reasoned that PKC-3 inhibition may selectively alter the molecular organization of PAR-6 and PKC-3 at the membrane relative to PAR-3, which would be consistent with the observed shift toward CDC-42-dependent PKC-3 assemblies.

To investigate these possibilities, we imaged PAR-3, PAR-6, and PKC-3 at the membrane using variable-angle epifluorescence microscopy (VAEM or pseudo-TIRF) ([@bib46]). All three proteins exhibit a distinct clustered appearance during the polarity establishment phase, consistent with reports of non-homogenous distributions of PAR proteins at the membrane ([Figures 4](#fig4){ref-type="fig"}A and [5](#fig5){ref-type="fig"}A, Establishment) ([@bib61], [@bib68], [@bib69]). Similar to previous analysis of PAR-6 ([@bib61]), we find that clusters of PAR-6, PAR-3, and PKC-3 move in a highly directional manner in the direction of cortical flow, coinciding with increasing overall asymmetry ([Figure 4](#fig4){ref-type="fig"}B and [Movie S5](#mmc6){ref-type="supplementary-material"}). While aPAR clusters have been noted ([@bib38], [@bib61], [@bib69]), the relationship between clustered and non-clustered PAR proteins and their ability to segregate in response to flow has not been explored.Figure 4Segregation of Anterior PAR Proteins Involves Cortical Clusters(A) Representative cortical images of PAR-3, PKC-3, CDC-42, and PH-PLCΔ1 in late-establishment and maintenance-phase zygotes along with zoom of inset region (yellow box).(B) Time-averaged cortical images spanning 180 s reveal anterior-directed tracks of cortical clusters of PAR-3, PAR-6, and PKC-3. Insets highlight the motion (arrows) of a representative single cluster in the image above.(C) Cluster index for the full dataset in (A) and PAR-6::GFP (images not shown). Significance between establishment and maintenance: p \< 0.01 for PAR-3, PAR-6, and PKC-3.(D) Representative midsection or cortical images of PAR-3::GFP (WT) or PAR-3ΔCR1::GFP (ΔCR1) with and without co-expression of the membrane tether PH::GBP (±GBP) shown at symmetry-breaking, establishment, or maintenance phase. Note enhancement of membrane signal visible in GBP-expressing zygotes viewed in midsection and lack of bright clusters of PAR-3ΔCR1::GFP viewed at the cortex.(E) Cluster index for WT and ΔCR1 in the presence of the PH-GBP membrane tether (+GBP) along with magnification of insets (yellow dashed-line rectangles in D) indicated to highlight the difference in clustering.(F) Representative midplane images of WT and ΔCR1 subject to GBP-membrane targeting showing defective segregation of ΔCR1. Images shown are from late-establishment phase.(G) Membrane intensity profiles for the full dataset represented in (F), showing average (solid line) and full range of data (shaded). Arrow highlights posterior expansion of the PAR-3 domain boundary.(H) ASI quantification of membrane intensity profiles in (G) showing significant reduction in asymmetry in the ΔCR1 mutant.^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. ns, not significant. Scale bars, 10 μm. See also [Movie S5](#mmc6){ref-type="supplementary-material"}.Figure 5Regulation of PKC-3/PAR-6 Cluster Association by PAR-3/CDC-42 Balance Tunes Responsiveness to Cortical Flows(A) Representative cortical images of PAR-6::GFP at late-establishment and maintenance-phase embryos for indicated conditions, shown along with a zoom of inset region (white boxes).(B) Cluster index measurements of full dataset reveal a gradient of cluster association across conditions. Note that clustering decreases when embryos enter maintenance phase, except for CRT90/*par-3*(*RNAi*) embryos, which show minimal clustering even in establishment phase.(C) ASI measurements of midsection images taken at late-establishment phase for a similar set of embryos as in (A) and (B), but expressing GFP::PKC-3, show a similar trend.(D) Profiles of membrane signal for zygotes in (C) showing average (solid line) and full range of data (shaded) reveal shift of the PKC-3 domain boundary (arrows) toward the anterior in *cdc-42*(*RNAi*) embryos and toward the posterior in CRT90-treated zygotes, resulting in significantly (p \< 0.01) smaller and larger domain sizes, respectively.(E) Combining clustering data from pseudo-TIRF imaging in (A) and (B) and (F) and (G) with ASI measurements of a complete GFP::PKC-3 dataset for late-establishment phase across all conditions allows us to plot cluster index versus ASI for the mean of each condition, revealing a strong correlation (linear regression: R^2^ = 0.85, p \< 0.01).(F--I) Representative cortical images (F, full zygote and inset zoom), cluster index (G), representative midsection images (H), and ASI (I) for late-establishment phase zygotes expressing GFP::PKC-3 in combination with either CDC-42(WT) or CDC-42 (Q61L). Yellow arrowheads in (H) highlight PKC-3 domain boundaries.(J) Profiles of membrane signal for zygotes in (I) showing average (solid line) and full range of data (shaded) highlight the posterior shift (black arrow) of the PKC-3 boundary in Q61L-expressing zygotes (p \< 0.05). Profiles for wild-type (solid black line) and CRT90-treated (dashed line) from (D) shown for comparison.(K) Quantification of the difference in boundary position between PAR-3 and PKC-3 in dual-labeled fixed zygotes for indicated conditions. Mean ± 95% CI (N) is shown. Positive values indicate reduced PKC-3 segregation relative to PAR-3. Representative images of PAR-3 and PKC-3 in zygotes overexpressing CDC-42(WT) of CDC-42 (Q61L). Yellow arrowheads indicate the posterior boundary of the PAR-3 or PKC-3 domains.(L and M) Comparison of cortical flow velocities (L) and PKC-3 asymmetry (M, ASI) for DMSO, CRT90, or *mlc-4*(*RNAi*) embryos taken at late-establishment phase.(N) A plot of PKC-3 ASI versus cortical flow rates for individual zygotes treated with DMSO, CRT90, or *mlc-4*(*RNAi*). Data points for individual embryos are shown with a 90% confidence boundary (shaded region).^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001. ns, not significant. Scale bars, 10 μm. See also [Figure S6](#mmc1){ref-type="supplementary-material"}.

To test whether clustering is a key driver of aPAR segregation, we examined whether PAR-3 transport depends on its ability to cluster. PAR-3 contains a conserved CR1 oligomerization domain, which is required for membrane binding and is targeted by PAR-1 kinase to induce displacement form the membrane ([@bib9], [@bib24], [@bib49], [@bib56]). We reasoned that this domain would be required for clustering; however, because mutations in the CR1 domain disrupt membrane binding ([Figure 4](#fig4){ref-type="fig"}D, WT versus ΔCR1), assessing clustering and segregation of a PAR-3ΔCR1 mutant requires an alternative mode of membrane targeting. We restored membrane localization of GFP:PAR-3ΔCR1 using a membrane-tethered anti-GFP nanobody (PH-GBP) and compared this with the behavior of GFP:PAR-3 (wild-type) that was also tethered to the membrane via PH-GBP. Targeting both wild-type and ΔCR1 to the membrane with PH-GBP reduces potential confounding effects of PAR-1-induced membrane displacement in the posterior. Thus, differences in segregation in PAR-3ΔCR1 relative to wild-type should be due to changes in clustering rather than differential sensitivity to PAR-1.

Consistent with oligomerization being required for clustering, membrane-tethered PAR-3ΔCR1 exhibited more diffuse membrane localization compared with wild-type controls ([Figures 4](#fig4){ref-type="fig"}D and 4E, WT + GBP versus ΔCR1 + GBP). PAR-3ΔCR1 also showed reductions in both segregation into the anterior and overall asymmetry ([Figures 4](#fig4){ref-type="fig"}F--4H and [Movie S5](#mmc6){ref-type="supplementary-material"}). Thus, the ability of the CR1 domain to drive formation of membrane-associated PAR-3 clusters ensures that PAR-3 is efficiently transported by cortical flows in addition to its known role in promoting membrane association.

Balance between PAR-3 and CDC-42 Assemblies Tunes Cortical Organization and Sensitivity to Cortical Flow {#sec2.5}
--------------------------------------------------------------------------------------------------------

The correlation between lack of PAR-3 clustering and defects in advective transport prompted us to examine the organization of anterior PAR proteins at the membrane in more detail. Although PAR-6 and PKC-3 exhibit a distinct clustered appearance similar to PAR-3 during polarity establishment, clusters are less pronounced and accompanied by a background of a more diffuse population ([Figures 4](#fig4){ref-type="fig"}A, 4C, and [5](#fig5){ref-type="fig"}A). By contrast, CDC-42 exhibits a more uniform signal overall that resembles typical membrane markers, such as the PIP~2~ (phosphatidylinositol-4,5-bisphosphate) probe PH-PLCΔ1 ([Figures 4](#fig4){ref-type="fig"}A and 4C). Membrane markers do exhibit enriched signals in membrane folds and protrusions, which are also enriched in the anterior, but these signals are clearly distinguishable from clusters.

With the transition into maintenance phase, clusters of PAR-6 and PKC-3 become less prominent and a diffuse population dominates. This change coincides temporally with a decrease in the prominence of PAR-3 clusters and an overall reduction in PAR-3 membrane localization ([Figures 4](#fig4){ref-type="fig"}A and 4C) as well as an increase in anterior CDC-42 activity ([Figures S5](#mmc1){ref-type="supplementary-material"}C--S5E) ([@bib47]). We therefore speculated that the mix of diffuse and clustered PAR-6/PKC-3 observed during establishment phase may reflect the distinct CDC-42- and PAR-3-dependent assemblies that we describe above. Consequently, cell-cycle-dependent changes in the balance between assembly types could effectively tune the system to promote efficient transport of aPAR species during the polarity establishment phase.

To test this hypothesis, we altered the balance between CDC-42- and PAR-3-dependent assemblies and monitored the corresponding changes in (1) organization at the membrane, and (2) segregation efficiency. In general, we find a striking correlation between quantitative measures of cortical clustering and overall asymmetry.

Depletion of CDC-42 is known to increase co-localization of PAR-6 with PAR-3 during polarity establishment ([@bib8]). We find that this also increases overall clustering of PAR-6 ([Figures 5](#fig5){ref-type="fig"}A and 5B). Examination of PKC-3 distributions clearly reveals enhanced segregation, with increased ASI ([Figure 5](#fig5){ref-type="fig"}C) and a visibly steeper domain boundary that is shifted toward the anterior ([Figure 5](#fig5){ref-type="fig"}D), resulting in a smaller anterior domain (^∗^p \< 0.01). Consistent with these data, we also observe a tighter coupling between the PAR-3 and PKC-3 domain boundaries in dual-labeled fixed zygotes ([Figure 5](#fig5){ref-type="fig"}K).

In contrast to CDC-42 depletion, inhibition of PKC-3 using CRT90, which favors CDC-42-dependent assemblies, shows reduced clustering of PAR-6, which could be reduced further by also depleting PAR-3 ([Figures 5](#fig5){ref-type="fig"}A and 5B). Under these conditions that favor CDC-42-dependent assemblies and reduced clustering, PKC-3 segregated less efficiently than DMSO controls, exhibited a reduced ASI, and failed to be fully excluded from the posterior ([Figures 5](#fig5){ref-type="fig"}C and 5D). To confirm that this reduction in clustering and segregation is due to favoring CDC-42-dependent assemblies, we examined the effect of expressing CDC-42 (Q61L), which stabilizes the active GTP-bound form of CDC-42 ([@bib1], [@bib83]). Unlike PKC-3 inhibition, CDC-42 (Q61L) does not efficiently bypass the normal dependence of PKC-3 on PAR-3 ([Figures S5](#mmc1){ref-type="supplementary-material"}F--S5J). This suggests that inhibition of PKC-3 favors CDC-42-associated assemblies via a mechanism distinct from stabilizing the GTP-bound form of CDC-42. However, similar to what we see when PKC-3 is inhibited, expression of CDC-42 (Q61L) reduced clustering and resulted in less efficient segregation of PKC-3 ([Figures 5](#fig5){ref-type="fig"}F--5K). Thus, regardless of the mechanism by which we alter the balance between PAR-3- and CDC-42-dependent assemblies, we achieve similar effects on clustering and segregation. This is particularly striking when we plot mean cluster index versus asymmetry across all conditions at establishment phase ([Figure 5](#fig5){ref-type="fig"}E).

Because PAR proteins are known to regulate actomyosin dynamics ([@bib15], [@bib61]), and changes in flow velocities could, in principle, affect advective transport ([@bib28]), we wanted to confirm that clustering rather than potential changes in flow velocity were the cause of reduced segregation efficiency. Measurements of flow rates from yolk granule motion in differential interference contrast (DIC) images allowed us to test the relationship between cortical flow rates and asymmetry in individual zygotes. Consistent with anterior PARs promoting their own segregation via stimulation of cortical flows, we find that PKC-3 inhibition results in a reduction of flow rates from approximately 6--10 μm/min in controls to approximately 2--5 μm/min in CRT90-treated embryos ([Figure 5](#fig5){ref-type="fig"}L). To test whether alterations in flow velocities could account for the observed segregation defects, we performed a partial depletion of MLC-4 to generate embryos with flow velocities of a similar range as observed in PKC-3-inhibited embryos ([Figure 5](#fig5){ref-type="fig"}L). Despite a similar range of flow velocities, MLC-4-depleted zygotes show a minimal reduction in asymmetry versus controls ([Figures 5](#fig5){ref-type="fig"}M and [S6](#mmc1){ref-type="supplementary-material"}A). Plotting flow velocity versus ASI reveals a weak decline in ASI as flow rates are reduced ([Figure 5](#fig5){ref-type="fig"}N). By contrast, CRT90-treated embryos show a lower ASI across the full range of observed flow rates (∼2--5 μm/min, [Figures 5](#fig5){ref-type="fig"}N and [S6](#mmc1){ref-type="supplementary-material"}A). Finally, to test whether restoring flows could rescue efficient segregation of PKC-3, we used RNAi to target the RhoGAPs, RGA-3/4, which results in excess actomyosin contractility and increased cortical flow rates ([@bib25], [@bib72]). Despite fully rescuing the moderate reduction in asymmetry of PAR-3 observed in *pkc-3*(*ts*) embryos to levels indistinguishable from wild-type, RGA-3/4 depletion failed to restore asymmetry of PKC-3 ([Figures S6](#mmc1){ref-type="supplementary-material"}B and S6C).

Together these data suggest that it is the failure of PKC-3 to associate with clusters rather than changes in flow rates that are the dominant factor in the decoupling between the localization of PAR-3 and PAR-6/PKC-3 observed in PKC-3-inhibited embryos. In fact, the resilience of PKC-3 asymmetry in embryos partially depleted of MLC-4 suggests that there is a relatively low threshold velocity required for efficient segregation of aPAR proteins by cortical flow, provided aPARs are able to associate normally into clusters.

We therefore conclude that although both PAR-3 and CDC-42 are critical for normal PAR-6/PKC-3 localization at the membrane in wild-type embryos, they drive formation of distinct aPAR assemblies, with distinct physical properties and responsiveness to cortical flow: PAR-3-dependent assemblies exhibit pronounced clustering, at least during the establishment phase, and are efficiently segregated by cortical flow. By contrast, CDC-42-dependent assemblies are more diffuse, likely reflecting enhanced diffusional mobility, and are inefficiently segregated by flow. Importantly, the balance between these two species appears to be subject to cell-cycle-dependent regulation to ensure maximal clustering and transport during the period of peak actomyosin cortical flows.

A PKC-3 Membrane-Targeting Assay Reveals Opposing Roles for PAR-3 and CDC-42 in Regulating PKC-3 Activity {#sec2.6}
---------------------------------------------------------------------------------------------------------

We next sought to explore whether there were other functional differences in these two types of assemblies. Specifically, we wondered whether PAR-3 and CDC-42 may have distinct regulatory effects on PKC-3 activity *in vivo*, which is difficult to analyze given their roles in PKC-3 membrane loading. While CDC-42 is generally thought to play an activating role ([@bib4], [@bib30], [@bib41], [@bib51], [@bib65]), the roles for PAR-3 and PAR-6 are less clear and may vary in different contexts ([@bib2], [@bib4], [@bib17], [@bib31], [@bib51], [@bib54], [@bib80]).

To directly assess whether PKC-3 activity differs in PAR-3-associated and CDC-42-associated assemblies *in vivo*, we targeted PKC-3 to the membrane by fusing it to the C1B domain of human PKCα, which can be induced to bind the membrane by the addition of phorbol ester ([Figure 6](#fig6){ref-type="fig"}A) ([@bib48]). This bypasses the membrane-binding requirement of PKC-3 on PAR-3, PAR-6, and CDC-42, allowing us to test their contribution to PKC-3 activity by monitoring membrane removal of the PKC-3 target, PAR-2.Figure 6PAR-3 and CDC-42 Have Opposing Regulatory Roles in an *In Vivo* PKC-3 Activity Assay(A) C1B targeting strategy for inducing PKC-3 membrane loading by PMA. PKC-3 kinase activity is monitored by following loss of PAR-2 from the membrane.(B) Zygotes expressing GFP::C1B alone (GFP::C1B-Ø) or GFP::C1B-PKC-3 along with mCherry::PAR-2 were subject to the indicated treatment. Note that uniform membrane targeting of C1B-PKC-3 leads to reduction of PAR-2 domain size, whereas omitting PMA or expressing C1B alone has no effect. Right: cartoon representation of results.(C) Quantification of PAR-2 domain size ratio for embryos shown in (B).(D) PAR-2 retention in GFP::C1B-PKC-3 expressing zygotes treated with PMA and CRT90 confirms that induced PAR-2 loss is dependent on PKC-3 kinase activity.(E) Zygotes expressing mCherry::PAR-2 with GFP::C1B-Ø or GFP::C1B-PKC-3 subject to *par-6*, *cdc-42*, or *par-3*(*RNAi*) before and 5 min after PMA addition.(F) Quantification of PAR-2 cortex retention comparing GFP::C1B-PKC-3 and GFP::C1B-Ø zygotes after treatment with PMA as in (E).Representative midsection confocal images are shown in (B), (D), and (E) before and 5 min after PMA/DMSO addition. ^∗∗∗^p \< 0.001. ns, not significant. Scale bars, 10 μm. See also [Figure S7](#mmc1){ref-type="supplementary-material"}; [Movies S6](#mmc7){ref-type="supplementary-material"} and [S7](#mmc8){ref-type="supplementary-material"}.

In the absence of phorbol ester, C1B-PKC-3 mirrors endogenous PKC-3 localization and is anteriorly enriched, with PAR-2 restricted to the posterior as in wild-type ([Figure 6](#fig6){ref-type="fig"}B, No PMA). Upon addition of 100 μM phorbol 12-myristate 13-acetate (PMA), C1B-PKC-3 is recruited uniformly to the membrane and the PAR-2 domain shrinks, consistent with an increase in posterior PKC-3 activity ([Figure 6](#fig6){ref-type="fig"}B, +PMA; [Figure 6](#fig6){ref-type="fig"}C; [Movie S6](#mmc7){ref-type="supplementary-material"}). The reduction in PAR-2 domain size is not seen in the absence of PMA, when targeting the C1B domain alone to the membrane, or if we inhibit PKC-3 with CRT90 ([Figures 6](#fig6){ref-type="fig"}B and 6D). The failure to completely remove PAR-2 in polarized zygotes is not simply due to PAR-2 being concentrated in a domain, because ectopic PAR-2 domains that form in meiotic arrest mutants, e.g., *mei-1* and *emb-27* ([@bib78]), are rapidly cleared ([Figure S7](#mmc1){ref-type="supplementary-material"}).

In *par-3*, *par-6*, or *cdc-42*(*RNAi*) zygotes, both endogenous PKC-3 and the C1B-PKC-3 fusion are cytoplasmic in the absence of PMA, allowing PAR-2 to localize uniformly to the membrane ([Figures 6](#fig6){ref-type="fig"}E and 6F). In *par-6* and *cdc-42*(*RNAi*) zygotes, membrane targeting of C1B-PKC-3 (+PMA) has no effect on PAR-2 distribution: it remains uniformly enriched at the membrane with no difference compared with controls in which C1B alone is targeted to the membrane ([Figures 6](#fig6){ref-type="fig"}E and 6F; [Movie S7](#mmc8){ref-type="supplementary-material"}). Thus, both PAR-6 and CDC-42 are required for PKC-3 activity *in vivo*.

By contrast, membrane targeting of C1B-PKC-3 in *par-3*(*RNAi*) zygotes induces rapid loss of PAR-2 from the membrane, with near complete removal within minutes ([Figures 6](#fig6){ref-type="fig"}E and 6F; [Movie S7](#mmc8){ref-type="supplementary-material"}). The displacement of PAR-2 is stronger than in wild-type zygotes, suggesting that PAR-3 normally acts to inhibit or suppress PKC-3 activity ([Figure 6](#fig6){ref-type="fig"}B, +PMA). Thus PAR-3 has two roles *in vivo*: it promotes PKC-3 membrane targeting while at the same time limiting its activation, reconciling *in vivo* reports whereby PAR-3 positively regulates PAR polarity ([@bib2], [@bib54]) with data indicating that PAR-3 can inhibit PKC-3 activity *in vitro* ([@bib31], [@bib51], [@bib74]).

Discussion {#sec3}
==========

Taken together, our data suggest that efficient polarization requires PKC-3 to cycle between functionally specialized modules of the anterior PAR network: a PAR-3-dependent module that segregates in response to symmetry-breaking signals, but which is inactive, and a CDC-42-dependent module that uses spatial information provided by PAR-3 to create an anterior domain of PKC-3 activity on the membrane ([Figure 7](#fig7){ref-type="fig"}).Figure 7Polarization through Coupling of PAR-3- and CDC-42-Dependent aPAR Assemblies(i) PKC-3 kinase activity ensures that PKC-3 loads via a PAR-3 intermediate, in which PKC-3 activity is suppressed. This dependence on PAR-3 can be bypassed upon inhibition of PKC-3 (dashed arrow). (ii) Clustering of membrane-associated PAR-3 allows it to be segregated by cortical flow into the anterior, carrying along associated PKC-3 molecules and generating asymmetric sites for further PKC-3 loading. (iii) PKC-3 activation requires conversion into a CDC-42-associated assembly, which relieves inhibition of PKC-3 by PAR-3. (iv) The CDC-42-dependent module is freely diffusible on the membrane and locally excludes pPARs. (v) Dissociation of CDC-42-dependent assemblies limits the spread of active PKC-3 at the membrane from the PAR-3 recruiting site. (vi) PKC-3 returns to the cytoplasm where it must load again via PAR-3.

In previous work, we showed that the diffusion and membrane dissociation rates of aPARs were in principle sufficient to explain segregation in response to flows ([@bib28]). Here we show that segregation of aPARs is directly linked to PAR-3-dependent clustering. Clustering reduces the effective diffusion of membrane-associated aPARs, which should favor advective transport. Alternatively, the sheer size of clusters may allow them to sense flow that would not affect individual proteins, possibly by allowing them to extend into the cortical actomyosin layer. Regardless of the physical mechanism, as we show here, clustering drives robust segregation of PAR-3 by cortical flow. This fact, coupled with PAR-3 exclusion from the posterior by PAR-1-dependent phosphorylation ([@bib60]), supports a model in which PAR-3 is responsible for sensing asymmetry-generating cues. Importantly, once it is asymmetric, PAR-3 provides a landmark for polarized loading of PAR-6/PKC-3, explaining recent observations that PAR-6 loads preferentially in the anterior of polarized embryos ([@bib69]).

Because our *in vivo* PKC-3 activity assay indicates that PKC-3 activity is suppressed within PAR-3-dependent assemblies, PAR-6/PKC-3 molecules must be converted into an activated CDC-42-dependent species, a state that we show is non-clustered and diffusive. Whereas this diffusive behavior of CDC-42-assemblies is a disadvantage for transport by cortical flow, it is an advantage for creating a uniform, wider-range field of PKC-3 activity that can efficiently exclude pPARs. If the same complexes had to respond to flow and exclude pPARs, there would be a trade-off between efficiency of transport by flow and uniformity of pPAR inhibition at the anterior.

For this field of activated CDC-42-dependent PKC-3 assemblies to remain coupled to the spatial information provided by PAR-3, two conditions must be satisfied. First, PKC-3 membrane localization must be dependent on PAR-3, and second, diffusion of CDC-42-associated PKC-3 away from loading sites must be limited, with PKC-3 ultimately being released back into the cytoplasm, where it again becomes dependent on PAR-3. This turnover restricts the effective distance these complexes can diffuse from their initial sites of formation, defining an effective "sphere of influence" around PAR-3 loading sites. Together, these requirements result in a cycle of localized membrane loading, activation, and release ([Figure 7](#fig7){ref-type="fig"}).

Our data suggest that the first of these requirements, PAR-3-dependent loading, is dependent on the kinase activity of PKC-3 itself, although the precise mechanism is unclear. Given the limited ability of CDC-42 (Q61L) to rescue PKC-3 membrane localization in PAR-3-depleted embryos, PKC-3 is likely to act at the step of CDC-42 complex generation, either inhibiting its own association with CDC-42, and/or destabilizing nascent CDC-42/PAR-6/PKC-3 assemblies. We speculate that it could be the very act of inhibiting PKC-3 through which PAR-3 promotes generation of stable CDC-42-dependent assemblies, but further work will be required to reveal the details of this molecular handover. Because the inhibitory role of PAR-3 appears to be broadly conserved ([@bib17], [@bib31], [@bib51], [@bib55], [@bib74]), this apparent paradoxical role of PAR-3 in promoting formation of membrane-associated aPKC complexes, yet also suppressing PKC-3 activity, may be a general feature of aPKC regulation.

How diffusion of CDC-42-associated PKC-3 is limited also remains unclear. Measurements elsewhere suggest that the distance these activated assemblies travel is on the order of 5--10 μm ([@bib27], [@bib68]), consistent with the PKC-3 gradient extending further into the posterior than PAR-3 during the establishment phase even in wild-type embryos (see [Figure 2](#fig2){ref-type="fig"}I). Because CDC-42 assemblies appear to be resistant to removal by posterior PAR proteins ([Figure 2](#fig2){ref-type="fig"}M), including the CDC-42 GAP CHIN-1, it seems likely that it is not preferential removal of these complexes in the posterior by pPARs, but rather the intrinsic lifetime of CDC-42-dependent PKC-3 assemblies that limits their diffusion into the posterior. This is compatible with a model in which aPKC undergoes asymmetric membrane loading but symmetric dissociation ([@bib68]).

By loading PKC-3 via what we presume is an inhibited PAR-3-associated state, which must then be activated, PKC-3 localization and activation are segregated into distinct modules of the PAR network, which can be regulated independently. This division of labor may be critical for PAR proteins, which operate across diverse contexts, where the polarity cues, substrates, scales, and even the concentrations of PAR molecules themselves may vary substantially. Even within the *C. elegans* zygote, the mechanisms of PAR segregation vary. During polarity establishment, when cortical flow is the major cue for anterior PAR segregation, PAR-3 clustering is prominent ([@bib15], [@bib28], [@bib61]). As the system enters the maintenance phase, flow ceases and continued aPAR segregation becomes dependent on the activity of PAR-1 and CHIN-1 ([@bib7], [@bib33], [@bib47], [@bib69]). Notably, clustering appears to be reduced during this phase, which [@bib19] show is dependent on PLK-1. This change in PAR molecular organization potentially reflects the shift in the spatial signals to which the PAR network must respond. At the same time, despite these changes, PKC-3 activity must remain efficient at displacing pPARs from the anterior domain, highlighting the adaptability of the PAR network.

In summary, here we have identified a critical role for the separation of signal-receiving and signal-transducing functions between modules of the aPAR network that are distinct, but coupled via dynamic exchange of the shared signaling component, PKC-3. We suggest that functional specialization of coupled modules resolves potential molecular constraints between components that must be sensitive to polarity cues and those that must propagate the signals. It further allows the system to independently modulate responsiveness to cues as well as the extent and strength of the output signal. The adaptability of such a paradigm suggests it is likely to be a common strategy in patterning systems.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Rabbit Anti-PAR-2([@bib20])N/ARabbit Anti-PAR-6([@bib30])N/ARat Anti-PKC-3([@bib77])N/AMouse Anti-PAR-3Developmental Studies Hybridoma BankP4A1; RRID: [AB_528424](nif-antibody:AB_528424){#interref0010}Mouse Anti-αTubulinSigmaDM1A (T9026); RRID: [AB_477593](nif-antibody:AB_477593){#interref0015}Rabbit Anti-pLLGL1/2(S650/S654)AbnovaPAB4657; RRID: [AB_1577970](nif-antibody:AB_1577970){#interref0020}α-rabbit-Alexa488/594/647Molecular ProbesRRID: [AB_2576217](nif-antibody:AB_2576217){#interref0025} / RRID: [AB_2534095](nif-antibody:AB_2534095){#interref0030} / RRID: [AB_2535813](nif-antibody:AB_2535813){#interref0035}α-mouse-Alexa488/594/647Molecular ProbesRRID: [AB_138404](nif-antibody:AB_138404){#interref0040} / RRID: [AB_141672](nif-antibody:AB_141672){#interref0045} / RRID: [AB_141725](nif-antibody:AB_141725){#interref0050}α-rat-Alexa488/594/647Molecular ProbesRRID: [AB_141373](nif-antibody:AB_141373){#interref0055} / RRID: [AB_141374](nif-antibody:AB_141374){#interref0060} / RRID: [AB_141778](nif-antibody:AB_141778){#interref0065}α-mouse-HRPDAKOP0447; RRID: [AB_2617137](nif-antibody:AB_2617137){#interref0070}α-rat-HRPDAKOP0450; RRID: [AB_2630354](nif-antibody:AB_2630354){#interref0075}**Bacterial and Virus Strains***E. coli*: OP50: *E. coli* B, uracil auxotrophCGCWB Strain: OP50*E. coli*: HT115(DE3): F-, mcrA, mcrB, IN(rrnD-rrnE)1, rnc14::Tn10(DE3 lysogen: lavUV5 promoter-T7 polymerase).CGCWB Strain: HT115(DE3)*E. coli* : DH5α Electrocompetent cellsGift from Colin DolphinN/A**Chemicals, Peptides, and Recombinant Proteins**aPKC inhibitor: CRT0103390Cancer Research Technology LTDCRT0103390phorbol 12-myristate 13-acetate (PMA)Sigma-AldrichCat\#P1585-1MGPKCι-(recombinant human baculovirus-expressed)EMD MilliporeCat\#14-505PKCζ-(recombinant active protein, His tagged, Sf21 cells-expressed)EMD MilliporeCat\#14-525FAM-PKCɛ-pseudosubstrateMolecular DevicesCat\#RP7548ATPSigma-AldrichCat\#A7699**Critical Commercial Assays**IMAP fluorescence polarization progressive binding systemMolecular Devices\#R8127KINOMEscanDiscoveRxN/A**Deposited Data**CRT0103390 synthesisPatentWO/2013/078126*pkc-3(ne4246)*Allele Sequence*ne4246***Experimental Models: Cell Lines**HEK-293Cell Production, Cancer Research UK (CRUK)HEK-293**Experimental Models: Organisms/Strains***C. elegans*: N2 (Bristol)CGCWB Strain: N2*C. elegans*: HT1593: *unc-119*(*ed3*) *III.*CGCWB Strain: HT1593*C. elegans*: DR466: *him-5*(*e1490*) *V.*CGCWB Strain: DR466*C. elegans*: DP38: unc-119(ed3) *III*; *daf-?.*CGCWB Strain: DP38*C. elegans*: JA1643*\[gfp*::*wsp-1*; *pkc-3*(*ts*)*\]*: *ojIs40 \[Ppie-1*::*gfp*::*GBDwsp-1 + unc-119*(*+*)*\]*;*pkc-3*(*ne4246*)*II*this paperJA1643*C. elegans*: JA1644\[*gfp*::*cdc-42*; *pkc-3*(*ts*)*\]*: *unc-119*(*ed3*) *III*; *tjIs6\[Ppie-1*::*gfp*::*cdc-42 + unc-119*(*+*)*\]*;*pkc-3*(*ne4246*)*II.*this paperJA1644*C. elegans*: JH2802\[*Dendra2*::*MEX-5\]*: *unc-119*(*ed3*) *III*; *axIs1950\[mex-5p*::*Dendra2*::*TEV*::*S-peptide*::*mex-5RR*::*mex-5 3\'UTR + unc-119*(*+*)*\]*CGCWB Strain: JH2802*C. elegans*: *JH2840\[mCherry*::*mex-5\]*: *axIs??? \[nmy-2p*::*pgl-1*::*GFP*::*patr-1*::*nmy-2 3\'UTR\]. axIs1731 \[pie-1p*::*mCherry*::*mex-5*::*pie-1 3\'UTR + unc-119*(*+*)*\]*CGCWB Strain: JH2840*C. elegans*: *KK1063\[lgl-1*::*gfp\]*: *it256 \[lgl-1*::*gfp + unc-119*(*+*)*\]*; *unc-119*(*ed4*) *III*; *lgl-1*(*tm2616*) *X*([@bib6])WB Strain: KK1063*C. elegans*: *KK114\[par-2*(*ts*)*\]*: *daf-7*(*e1372*) *par-2*(*it5*) *III*CGCWB Strain: KK114*C. elegans*: *KK1216\[par-3*::*gfp\]*: *par-3*(*it298 \[par-3*::*gfp\]*) *III*Ken Kemphues / CGCWB Strain: KK1216*C. elegans*: *KK1228\[gfp*::*pkc-3\]*: *pkc-3*(*it309 \[gfp*::*pkc-3\]*) *II*Liam Coyne\
Ken Kemphues / CGCWB Strain: KK1228*C. elegans*: *KK1248\[par-6*::*gfp\]*: *par-6*(*it310\[par-6*::*gfp\]*) *I*Anushae Syed\
Ken Kemphues / CGCWB Strain: KK1248*C. elegans*: *KK1262\[par-1*::*gfp\]*: *par-1* (*it324\[par-1*::*gfp*::*par-1 exon 11a\]*)Diane Morton / CGCWB Strain: KK1262*C. elegans*: *KK822\[par-1*(*ts*)*\]*: *par-1*(*zu310*) *V*CGCWB Strain: KK822*C. elegans*: *KK973\[par-3*:Δ*cr1*:*gfp\]*: *itIs169 \[Ppar-3*::*par-3 CR1 Δ*(*69-82*):::*gfp*, *unc-119*(*+*)*\]*; *unc-119*(*ed4*) *III*Ken KemphuesKK973*C. elegans*: *NWG0003\[par-2*(*ts*); *gfp*::*par-6\]*: *daf-7*(*e1372*) *par-2*(*it5*) *III*; *unc-119*(*ed3*) *III*; *ddIs8 \[gfp*::*par-6*(*cDNA*); *unc-119*(*+*)*\]*this paperNWG0003*C. elegans*: *NWG0012\[gfp*::*c1b\]*: *unc-119*(*ed3*)*III*; *crkIs4\[Ppie-1*::*sfgfp*::*c1b*::*pie-1utr*; *unc-119*(*+*)*\]*this paperNWG0012*C. elegans*: *NWG0016\[gfp*::*c1b*::*pkc-3\]*: *unc-119*(*ed3*)*III*; *crkIs10\[Ppie-1*::*sfgfp*::*c1b*::*pkc-3*::*pie-1utr*; *unc-119*(*+*)*\]*this paperNWG0016*C. elegans*: *NWG0021\[gfp*::*c1b*::*pkc-3*;*mCherry*::*par-2\]*:*unc-119*(*ed3*)*III*; *ddIs31\[pie-1p*::*mCherry*::*par-2*::*pie-1utr*; *unc-119*(*+*)*\]*; *crkIs10\[Ppie-1*::*sfgfp*::*c1b*::*pkc-3*::*pie-1utr*; *unc-119*(*+*)*\]*this paperNWG0021*C. elegans*: *NWG0022\[gfp*::*c1b*;*mCherry*::*par-2\]*: *unc-119*(*ed3*)*III*; *ddIs31\[pie-1p*::*mCherry*::*par-2*::*pie-1utr*; *unc-119*(*+*)*\]*; *crkIs4\[Ppie-1*::*sfgfp*::*c1b*::*pie-1utr*; *unc-119*(*+*)*\]*this paperNWG0022*C. elegans*: *NWG0026\[par-6*::*gfp*; *mCherry*::*par-2\]*: *par-6*(*it310\[par-6*::*gfp\]*) *I*;*unc-119*(*ed3*)*III*; *ddIs31\[pie-1p*::*mCherry*::*par-2*; *unc-119*(*+*)*\]*this paperNWG0026*C. elegans*: *NWG0027\[gfp*::*pkc-3*; *mCherry*::*par-2\]*: *pkc-3*(*it309 \[gfp*::*pkc-3\]*) *II*;*unc-119*(*ed3*)*III*; *ddIs31\[pie-1p*::*mCherry*::*par-2*; *unc-119*(*+*)*\]*this paperNWG0027*C. elegans*: *NWG0028\[par-3*::*gfp*; *mCherry*::*par-6\]*: *par-3*(*it298 \[par-3*::*gfp\]*) *III*;*unc-119*(*ed3*)*III*;*ddIs26\[mCherry*::*T26E3.3*;*unc-199*(*+*)*\]*this paperNWG0028*C. elegans*: *NWG0039\[par-1*(*ts*); *par-6*::*gfp\]*: *par-1*(*zu310*) *V*; *par-6*(*it310\[par-6*::*gfp\]*) *I.*this paperNWG0039*C. elegans*: *NWG0047\[*PH-GBP\]: *unc-119*(*ed3*) *III*; *crkEx1\[pNG19*: *mex-5p*::*PH*(*PLC1Δ1*)::*GBP*::*mKate*::*nmy-2UTR + unc-119*(*+*)*\]*; *him-5* (*e1490*) *V.*this paperNWG0047*C. elegans*: *NWG0053\[par-6*::*gfp*;*pkc-3*(*ts*)*\]*: *par-6*(*it310\[par-6*::*gfp\]*) *I*; *pkc-3*(*ne4246*)*II*this paperNWG0053*C. elegans*: *OD70\[mCherry*::*PH-PLCΔ1\]*: *unc-119*(*ed3*) *III*; *ltIs44\[pie-1p-mCherry*::*PH*(*PLC1Δ1*) *+unc-119*(*+*)*\] V*([@bib42])WB Strain: OD70*C. elegans*: *SA131\[gfp*::*cdc-42\]*: *unc-119*(*ed3*)*III*; *tjIs 6\[Ppie-1*::*gfp*::*cdc-42+unc-119*(*+*)*\]*([@bib59])WB Strain: SA131*C. elegans*: *TH129\[gfp*::*par-2\]*: *unc-119*(*ed3*)*III*;*ddIs25\[GFP*::*F58B6.3*;*unc-119*(*+*)*\]*;([@bib72])TH129*C. elegans*: *TH159\[mCherry-cdc-42\]*: unc-119(ed3)III; ddls46\[WRM0625bA11 GLCherry::cdc-42; Cbr-unc-119(+)\]Tony HymanTH159*C. elegans*: *TH209\[mCherry*::*par-2\]*: *unc-119*(*ed3*)*III*; *ddIs31\[pie-1p*::*mCherry*::*par-2*; *unc-119*(*+*)*\]*([@bib72])TH209*C. elegans*: *TY3558\[gfp*::*his-11*; *b-tubulin*::*gfp\]*: *ruls\[pie-1*::*GFPhis-11\] III*; *ojIs1 \[β-tubulin*::*GFP\]*CGCWB Strain: TY3558*C. elegans*: *UE37\[pie-1*::*gfp\]*: *axEx73 \[pie-1p*::*pie-1*::*GFP + rol-6*(*su1006*) *+ N2 genomic DNA\]*; *tubulin mCherry*Carrie CowanUE37*C. elegans*: *WH423\[mCherry*::*cdc-42*(*Q61L*)*\]*: *Ppie-1*::*mcherry*::*cdc-42*(*Q61L*)([@bib47])WH423*C. elegans*: *WH497\[gfp*::*chin-1\]*: *ojls69\[pie-1*::*mGFP*::*chin-1 + unc-119*(*+*)*\]*CGCWB Strain: WH497*C. elegans*: *WH517\[gfp*::*wsp-1\]*: *ojIs40 \[Ppie-1*::*gfp*::*GBDwsp-1 + unc-119*(*+*)*\]*CGCWB Strain: WH517*C. elegans*: *WM150\[pkc-3*(*ts*)*\]*: *pkc-3*(*ne4246*) *II*([@bib25])WM150*C. elegans*: *WS5018\[gfp*::*cdc-42\]*: *cdc-42*(*gk388*); *opIs295 \[cdc-42p*::*gfp*::*cdc-42*(*genomic*)::*cdc-42 3\'UTR + unc-119*(*+*)*\] II.*([@bib62])WB Strain: WS5018**Oligonucleotides**pkc-3(genomic) fwd:CCC[ACTAGT]{.ul}ATGTCGTCTCCGACAT ([SpeI]{.ul})IDT DNAN/Apkc-3(genomic) rev:CCC[AGGCCT]{.ul}TCAGACTGAATCTTCC (StuI)IDT DNAN/APH-GBP gBlock:\
fwd: TTCCGTTTTCTCATTGTATTCTCTCIDT DNAN/APH-GBP gBlock:\
rev: ATGATGCCGGCTTAGCTAGCIDT DNAN/ASite-directed mutagenesis (PAM site) in pNG0018,\
fwd: GTCTGTTTCGTAACTGTCTTCTGTATAACTIDT DNAN/ASite-directed mutagenesis (PAM site) in pNG0018,\
fwd: TGATATCGAAACAAACACTGIDT DNAN/Actl (RNAi): fwd: ATCGATAAGCTTTGTATCCTCTTGIDT DNAN/Actl (RNAi): rev: ACCGGCGGATCCTTAAATACGGIDT DNAN/A**Recombinant DNA**Fosmid: WRM069dD11Source BioScienceWB Clone: WRM069dD11Plasmid: L4440Addgeneplasmid\#1654Plasmid: pUC57-C1B(codon-optimized)GenScriptN/APlasmid: pTH699Gift from Tony HymanN/APlasmid: pC1B-ØThis paperN/APlasmid: pC1B-pkc-3This paperN/APlasmid: CmKate2 MosSci vectorGift from Tony HymanN/APlasmid: pNG0018This paperN/APlasmid: pNG0019This paperN/AAhringer Feeding RNAi: *cdc-42*Source BioScienceWB Clone: sjj_R07G3.1Ahringer Feeding RNAi: emb-27Source BioScienceWB Clone: sjj_F10B5.6Ahringer Feeding RNAi: *par-3*Source BioScienceWB Clone: sjj_F54E7.3Ahringer Feeding RNAi: *par-6*Source BioScienceWB Clone: sjj_T26E3.3Ahringer Feeding RNAi: *pkc-3*Source BioScienceWB Clone: sjj_F09E5.1Ahringer Feeding RNAi: *perm-1*Source BioScienceWB Clone: sjj_T01H3.4Ahringer Feeding RNAi: *rga-3*Source BioScienceWB Clone: sjj_K09H11.3Ahringer Feeding RNAi: *cgef-1*Source BioScienceWB Clone: sjj_C14A11.3Feeding RNAi: *mlc-4*([@bib66])N/AFeeding RNAi: control(ctl)This paperN/APH-GBP gBlock (sequence on request)IDT DNAN/Actl (RNAi): gBlock (sequence on request)IDT DNAN/A**Software and Algorithms**MatlabMathworksR2016aKilfoil Feature Tracking (feature2D.m)<http://people.umass.edu/kilfoil/downloads.html>N/AFiji (ImageJ)<https://fiji.sc/#>N/AActivityBaseIDBSN/A

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Josana Rodriguez (<josana.rodriguez@ncl.ac.uk>[)]{.ul}. CRT0103390 may be obtained through an MTA from Cancer Research Technology (<jroffey@cancertechnology.com>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### *C. elegans* Strains and Maintenance {#sec4.3.1}

*C. elegans* strains were maintained on nematode growth media (NGM) under standard conditions ([@bib12]) at 16°C or 20°C unless otherwise indicated. Strains listed in the [Key Resources Table](#sec4.1){ref-type="sec"}. Note analysis of zygotes precludes determination of animal sex.

### *C. elegans* Transgenic Animals {#sec4.3.2}

Following the scheme of ([@bib48]), a codon-optimized ([@bib67]) sequence encoding the C1B domain from human PKCα (GenScript) was inserted into pTH699 via BamHI and SmaI to generate a *sfgfp::c1b* fusion under control of the *pie-1* promoter and -3' UTR (pC1B-Ø). Genomic *pkc-3* was amplified from fosmid WRM069dD11 (Source BioScience, WB Clone: WRM069dD11) using the following primers (fwd:cccactagtatgtcgtctccgacat; rev:cccaggccttcagactgaatcttcc) and inserted into (pC1B-Ø) using SpeI and StuI to generate pC1B-pkc-3. Both plasmids were introduced by biolistic bombardment into HT1593 worms ([@bib64]), yielding NWG0012 and NWG0016.

The membrane-tethered GFP-binding protein (PH-GBP) was generated by combining amino acids 1-175 corresponding to the PH domain of rat PH-PLCΔ1 ([@bib5]) and VHH4GFP ([@bib14]) coupled by a SGQGGSGGSGGS linker. The resulting sequence was codon-optimized (CAI = 0.49) and a single GFP intron inserted as described ([@bib67]). A synthetic gBlock (IDT DNA) encoding the PH-GBP was PCR amplified and cloned in frame with a C-terminal codon-optimized mKate2 under the control of the *mex-5* promoter and *nmy-2* 3' UTR in a MosSCI vector containing wild-type *unc-119* obtained from the Hyman Lab. The resulting plasmid (pNG0018) was inserted at the ttTi5605 *mos1* site locus of DP38 worms via CRISPR after mutating the sgRNA/PAM site following the method described (pNG0019) ([@bib18]). Modified worms were crossed into DR466 to generate a stable male line expressing PH-GBP (NWG0047). To rescue membrane localization of PAR-3 variants, we crossed NWG0047 with KK1216 (*par-3*::*gfp*) or KK973 (*par-3Δcr1*::*gfp*) lines. We were unable to obtain a stable homozygous line for the endogenously tagged PAR-3::GFP, presumably due to the toxic effects of continuously targeting all PAR-3 to the membrane throughout embryogenesis. Thus, we used F1 progeny heterozygous for PAR-3::GFP for analysis. By contrast, for PAR-3ΔCR1::GFP, which is expressed ectopically from a multi-copy random insertion, we readily obtained animals homozygous for both PAR-3ΔCR1::GFP and PH-GBP, which were used for subsequent analysis. However, no significant difference in the segregation of PAR-3ΔCR1::GFP was seen between heterozygous and homozygous animals.

For analysis of GFP::CDC-42, SA131 was used unless otherwise indicated.

For analysis of the effects of CDC-42(Q61L) on GFP::PKC-3 localization, zygotes were taken from F1 animals resulting from crossing KK1228 with either TH159 or WH423 due to difficulties obtaining stable animals homozygous for both markers.

### Cell Lines {#sec4.3.3}

HEK-293 are female and were obtained from Cell Production, Cancer Research UK (CRUK) and cultivated in DMEM (Dulbecco's modified Eagle's medium), 10% FBS (fetal bovine serum) and penicillin--streptomycin (Invitrogen) ([@bib45]).

### Bacterial Strains {#sec4.3.4}

OP50 bacteria and HT115(DE3) were obtained from CGC. DH5α was obtained from Colin Dolphin. Feeding by RNAi used HT115(DE3) bacteria strains containing a plasmid carrying the indicated RNAi feeding plasmid.

Method Details {#sec4.4}
--------------

### *C. elegans* - RNAi Culture Conditions {#sec4.4.1}

RNAi by feeding was performed similar to described methods ([@bib43]). Briefly, HT115(DE3) bacterial feeding clones were inoculated from LB agar plates to LB liquid cultures and grown overnight at 37°C in the presence of 10 μg/ml carbenicillin. Bacterial cultures were induced with 5 mM IPTG at 37° for 4h with agitation before spotting 100 μl of induced bacteria onto 60 mm agar RNAi plates (10 μg/ml carbenicillin, 1 mM IPTG). L4 larva were added to RNAi feeding plates and incubated for 24-72 hr depending on gene and temperature. For temperature sensitive lines, feeding was performed at 15°C for 48-72 hr and shifted to 25°C for 2-5 hr before imaging. For double depletion experiments, L3/L4 larva carrying *par-1*(*zu310*) or *par-2*(*it5*) temperature sensitive mutants were placed on RNAi plates at 15°C for 24 hr before a fraction of those were moved to fresh RNAi expressing plates for 18 to 22 hr at 25°C. Partial RNAi for *mlc-4* was performed for 14-24 hr at 20°C. For partial depletion of *perm-1*, *rga-3*/*4* or *pkc-3*, bacteria expressing the desired clone were mixed at the indicated ratios with bacteria expressing control RNAi. *par-3*, *par-6*, *cdc-42*, *pkc-3*, *perm-1*, rga-3/4, *cgef-1* and *emb-27* clones are from the Ahringer library ([@bib43]). *mlc-4* is from [@bib66]. A control RNAi clone was generated by synthesizing a random 500bp sequence using the Matlab random number generator with no homology to the worm genome, cloned into Bgl-II / HindIII sites of L4440 (Addgene, plasmid\#1654), and transformed into HT115 bacteria.

### *C. elegans* Embryos -- Western Blots {#sec4.4.2}

Embryos were obtained by a standard bleaching protocol and resuspended in NuPAGE LDS sample buffer (Invitrogen) prior to sonication using the Biorupture (Diagenode) for 5 - 30 s on, 30 s off cycles. Samples were heated at 70°C for 10 min before centrifugation at 13.000 rpm for 20 min to obtain cleared supernatant. Samples were run on a 12% NuPAGE gel using MOPS SDS running buffer (Invitrogen) and transferred onto PVDF membrane (Immobilon-P membrane 0.45 um, Millipore). PKC-3 and tubulin was detected using the primary (anti-PKC-3 1:10.000 and anti-tubulin 1:20.000) and secondary antibodies (as recommended by provider) indicated in [Key Resources Table](#sec4.1){ref-type="sec"} and detected via chemiluminescence (ECL prime, GE Healthcare Life Sciences). PKC-3 band intensity was analyzed using the Fiji Gel analysis tool.

### *C. elegans* Zygotes -- Drug Treatment {#sec4.4.3}

All drug treatment experiments were performed in 10 to 50% *perm-1*(*RNAi*) ([@bib13]). Drugs were dissolved in DMSO and used at the following concentrations: phorbol 12-myristate 13-acetate (PMA, Sigma-Aldrich, P1585-1MG), 100 μM; CRT90 (CRT0103390, Cancer Research Technology LTD), 10 μM. When drug treatment alone was required, we obtained zygotes with permeable eggshells by placing L4 animals on a 1:1 mix of bacteria expressing *perm-1*(*RNAi*) and *ctl* (*RNAi*) for 16 to 20 hr at 20°C. When drug treatment was combined with additional RNAi treatment, L4 animals were placed on bacteria expressing *perm-1*(*RNAi*) mixed at a 1:9 ratio with bacteria expressing the desired RNAi (*par-3*, *par-6*, *cdc-42*, *control*) and incubated for 40-48 hr at 20°C.

### *C. elegans* Zygotes - Immunofluorescence {#sec4.4.4}

Immunofluorescence was performed as previously described ([@bib3]). Briefly, gravid hermaphrodite worms were washed and then transferred to a 7 μl drop of M9 on a 0.1% poly-lysine coated well. Embryos were released using a needle and then covered with a coverslip to compress the embryos. Slides were snap-frozen on dry ice for 30 min after which the coverslip was quickly removed and the slide fixed in methanol at room temperature for 20 min. Samples were washed and re-hydrated with PBS followed by two 10 min washes in PBS+0.2% Tween-20 before proceeding with antibody incubations, DAPI staining and mounting in Mowiol (Sigma-Aldrich). All antibodies used in this study are listed in [Key Resources Table](#sec4.1){ref-type="sec"}. Primary antibody dilutions used: anti-PAR-2 1:500, anti-PAR-6 1:10, anti-PKC-3 1:500 and anti-PAR-3 1:50. Secondary antibodies were used as recommended by provider. Confocal images were acquired using Carl Zeiss Axioplan 2, LSM510 Meta confocal equipped with LSM image software and Nikon A1R equipped with Nikon elements software and a 63× objective. Cortical super-resolution images were acquired using the DeltaVision OMX system equipped with SoftWoRx and OMX acquisition software. Secondary processing of images was performed using Photoshop CS5 and Illustrator CS5 (Adobe).

### *C. elegans zygotes -* Live Imaging {#sec4.4.5}

Embryos were dissected in 2-4 μl of M9 buffer (22 mM KH~2~PO~4~, 42 mM NaHPO~4~, 86 mM NaCl and 1 mM MgSO~4~) on a coverslip and mounted under 2% agarose pads ([@bib85]) or dissected in Shelton's Growth Medium ([@bib22]) and mounted with 16-21 μm polystyrene beads between a slide and coverslip and sealed with VALAP ([@bib27]). 16-18 μm beads were used for cortex imaging to maximize imaging surface. In all other cases, 21 μm beads were used to minimize compression effects on development. For CRT90 experiments, embryos were dissected in the presence of 10 μM CRT90. For C1B targeting experiments, two sides of the coverslip were left unsealed to create a flow chamber ([@bib27]) and PMA washed in at the indicated times.

To maximize viability, embryos were typically imaged at 20-22°C, except for temperature sensitive alleles, which were imaged at the indicated temperatures using an objective temperature control collar (Bioptechs / Linkam, PE94). For consistency, establishment phase embryos were taken at pronuclear meeting, and maintenance phase was defined as the interval from nuclear envelope breakdown to metaphase.

Cortex images were captured with a 100x 1.49 NA TIRF objective on a Nikon TiE (Nikon) equipped with an iLas2 TIRF unit (Roper), 488 or 561 fiber coupled diode lasers (Obis), and an Evolve Delta camera (Photometrics). Midplane imaging was performed on Carl Zeiss Axioplan 2, LSM510 Meta confocal or a Nikon TiE with 63x or 100x objectives, further equipped with either a Spectra-X LED light source (wide-field) or a custom X-Light V1 spinning disk system (CrestOptics, S.p.A.) with 50μm slits, 488, 561 fiber-coupled diode lasers (Obis) and either a CoolSnap HQ or Evolve Delta (Photometrics). Imaging systems were run using Metamorph (Molecular Devices) and configured by Cairn Research (Kent, UK).

### *In vitro* PKC Enzyme Assays {#sec4.4.6}

The ability of compounds to inhibit the kinase activity of recombinant human baculovirus-expressed full-length PKCι was measured using the IMAP fluorescence polarization (FP) progressive binding system (Molecular Devices \#R8127, Sunnyvale, CA) in 384-well black, non-binding, flat-bottom assay plates (Corning \#3575, Corning, NY). The assay mixture (final volume = 10 μL) contained 20 mM Tris-HCL (pH 7.5), 150 μM ATP, 10 mM MgCl2, 0.01% Triton X-100, 250 μM EGTA, 1 mM DTT, 15 pM PKCι (EMD Millipore \#14-505, Billerica, MA), 100 nM FAM-PKCɛ-pseudosubstrate (Molecular Devices \#RP7548), 0.1% DMSO and various concentrations of test compound. Compound dilutions (prepared in 100% DMSO) were added to the assay plate at 100 nL using the BioMek NX pin tool (Beckman Coulter, Indianapolis, IN). Enzyme reactions were initiated by the addition of ATP (Sigma- Aldrich \#A7699, St. Louis, MO), followed by incubation of the plates for 1 hour in a 25°C incubator. A 20 μL aliquot of IMAP detection reagent (1:400 in 85% 1X Binding Buffer A and 15% 1X Binding Buffer B) was added to each well followed by a 2-hour incubation at 25°C. Fluorescence polarization was then measured using the PerkinElmer Envision 2102 multi-label plate reader (PerkinElmer, Waltham, MA) using the FP dual mirror, FP480 excitation filter and P-pol 535 and S-pol 535 emission filters. Data analysis was performed using ActivityBase (IDBS, Guilford, UK). IC~50~ values were calculated by plotting percent inhibition versus log10 of the concentration of compound and fitting to the 4-parameter logistic model (top and bottom constrained to 100 and 0, respectively) in XLFit 4 (IDBS).

The PKCζ kinase assay was performed using the IMAP FP progressive binding system as described above for PKCι but with some modifications. The concentration of PKCζ (recombinant active protein, His tagged, expressed in Sf21 cells, Millipore, 14-525) was 10pM, while the substrate concentrations were 100 nM and 40 μM for the FAM-PKCɛ-pseudosubstrate (Molecular Devices \#RP7548) and ATP, respectively.

### Cellular Biochemical Assay {#sec4.4.7}

HEK-293 cells were transfected in a 10 cm dish as per the manufacturer's instructions (Corning). After 16 hr, the cells were trypsinized and seeded into a 96-well plate at 1.5×10^4^ cells/well and medium was replenished. After a further 24 hr, the medium was replaced by new medium and a range of CRT0103390 inhibitor concentrations. After 1 hr of inhibitor treatment, lysates were prepared using ice-cold Tris lysis buffer \[150 mM NaCl, 20 mM Tris (pH 7.5), 1 mM EGTA, 1 mM EDTA and 1% Triton X-100\]. Lysates were transferred on to an anti-FLAG-coated ELISA plate (Sigma) and incubated for 2 hr with gentle shaking, followed by an automated wash step (Tecan plate washer) with wash buffer \[50 mM Tris (pH 7.5), 0.15 M NaCl and 0.02% Tween 20\]. The immunocomplexed protein was incubated with anti-pLLGL1/2 (S650/S654) primary antibody overnight at 4°C, followed by an automated wash and then addition of HRP-conjugated secondary antibody. After a further wash, 3,3',5,5'-tetramethylbenzidine (Sigma) was added according to the manufacturer's instructions and attenuance was read at 450 nm using an Ascent plate reader (Thermo Labsystems).

### Kinase Selectivity {#sec4.4.8}

CRT0103390 was profiled using the KINOMEscan *in vitro* competition binding screening platform at DiscoveRx against a panel of 442 mutant and non-mutant kinases at a test concentration of 1 μM. Selectivity scores were calculated as the number of non-mutant kinases with % activity relative to control \< 20/number of non-mutant kinases tested. CRT0103390 demonstrated a high degree of selectivity in this panel, with an S(80) of 0.09.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

### Image Analysis - General {#sec4.5.1}

All image analysis was performed in Fiji (ImageJ)([@bib70]) and Matlab (Mathworks).

### Image Analysis - Asymmetry Index (ASI) {#sec4.5.2}

The asymmetry index (ASI) of a feature is defined by:$$\frac{A - P}{2\left( A + P \right)}$$where A and P define the anterior and posterior signal, respectively. Raw ASI values are normalized to the mean ASI observed in respective controls, such that a value of 1 indicates wild-type asymmetry and zero indicates complete loss of asymmetry. Anterior and posterior signals are defined depending on the condition examined and include cross-sectional area (AB vs P1 asymmetry), fluorescence intensity on the two cell halves for the membrane (midsection PAR analysis) or cytoplasm (MEX-5, PIE-1), or cluster number (CHIN-1).

### Image Analysis -- Cluster Index {#sec4.5.3}

The Cluster Index is defined as the variance in cortical intensity within the anterior domain. It was calculated in Matlab across user specified ROIs that were subject to background subtraction and normalization to mean intensity before analysis.

### Image Analysis -- CHIN-1 Foci {#sec4.5.4}

CHIN-1 foci were identified using the feature2D.m script, part of the feature detection and particle tracking package from the Kilfoil Lab ([@bib63]). Embryos were automatically detected and partitioned into 3 domains (Anterior, Middle, Posterior) and normalized anterior vs posterior particle densities used for ASI calculation.

### Image Analysis -- MEX-5 Mobility {#sec4.5.5}

For MEX-5 mobility, five pre-bleach frames were captured by spinning disk confocal microscopy. A central 20-pixel wide stripe was then bleached along the AP axis using a 473 diode laser (Obis) and recovery was monitored every 2 s. Because MEX-5 is uniform in the quantified conditions, fluorescence was monitored within a central 20 x 100-pixel box.

### Image Analysis - Colocalization {#sec4.5.6}

Colocalization analysis of PAR-6 and PAR-3 was performed in ROIs at the anterior cortex of establishment phase zygotes (wild-type n=8 and *pkc-3*(*ts*) n=9). Costes' Mask and intensity correlation quotient ([@bib50]) were obtained using JaCOP plug-in in Fiji.

### Image Analysis -- Flow Speeds {#sec4.5.7}

Anterior-directed cortical flow speed during establishment phase was measured using midplane, brightfield images acquired every second until late establishment phase at which point we switched to fluorescent imaging to obtain suitable images for measuring PAR asymmetry. Using the Kymograph Plugin in Fiji ([@bib73]), we generated kymographs for individual embryos by tracing a segmented line along the cortex starting at the origin of flow. A minimum of 10 yolk granule trajectories, each spanning approximately 200s were selected for a minimum of 5 embryos per condition. The cortical flow velocity was defined as the total distance over time calculated from a line connecting the start and end positions of the granule on the kymograph. Measurement of cortical flow in wild-type embryos expressing GFP fusions to PAR-3, PKC-3 or CDC-42 yielded a velocity of 7.1+/-1.4 μm/min (n=22), consistent with previously published values (7.66+/-1.0 μm/min, n=6)([@bib61]).

### Image Analysis -- Anterior Cortical Intensity (Immunofluorescence) {#sec4.5.8}

Anterior cortical intensity of each PAR protein is the mean greyscale value of a line 2 pixels wide (in each corresponding fluorescent channel) covering the PAR-3 cortical domain of the zygote. The cortical intensity value is then normalized by dividing it by the mean greyscale value of a nearby cytoplasmic region to correct for embryo IF staining variability. In *par-3*(*RNAi*) zygotes, we cannot distinguish anterior from posterior cortex and the entire cortex of zygotes is analyzed. Each experimental condition was analyzed in three independent experiments.

### Image Analysis -- Anterior PAR Retraction (Immunofluorescence) {#sec4.5.9}

The posterior boundary of anterior PARs in fixed, midsection fluorescent images is defined at the intersection between the equatorial zygote line (longest line linking the zygotes' poles) and the line that links the cortical ends (top and bottom) of the PAR protein analyzed. Retraction is the distance between this posterior boundary and the posterior pole of the zygote. Retraction difference is defined as the difference in retraction distance between PAR-3 and PKC-3. Data were collected from three independent experiments.

### Image Analysis -- Intensity Profile Extraction {#sec4.5.10}

In general, to assess PAR signal from midsection images, a 60-pixel wide stripe encompassing the cell membrane was extracted and straightened to generate a profile for each embryo for further analysis.

For spatial analysis (ASI, profile plots, domain size, segregation efficiency), the top 4 central pixels corresponding to the membrane were taken at each x-position and averaged to the given local membrane signal. Background and cytoplasmic signal were calculated locally from inner and outer edges of this stripe, allowing normalization for variation in signal between conditions. Briefly, background was subtracted and then membrane divided by cytoplasmic intensity.

### Image Analysis -- PAR-3 versus PKC-3 Cortical Profile Comparison (Immunofluorescence) {#sec4.5.11}

To quantitatively compare PAR cortical profiles in multi-labelled fixed embryos, two identical profiles along the cortex were extracted in each channel as above. Each set of profiles was split in half to generate two boundary regions. After normalization to maximum and minimum values, profiles were registered using the inflection point, c, based on fitting each PAR-3 profile using the following function:$$I\left( x \right) = a + \frac{b}{2}\left( {erf\left( {mx - c} \right)} \right)$$where erf is the error function, c is the domain boundary position, m the boundary slope and a and b allow for scaling and displacement on the y-axis.

### Image Analysis -- Domain Size/Segregation Efficiency {#sec4.5.12}

To extract domain size data (PAR-2 domain size change, segregation efficiency) from single channel images, cortical fluorescence profiles were normalized to total embryo perimeter length and aligned to the center of posterior PAR domain determined by fitting the profile to the following function:$$I\left( x \right) = a \pm \frac{b}{2}\left( {erf\left( {mx - c_{1}} \right) - erf\left( {mx - c_{2}} \right)} \right)$$with the center of the posterior domain specified by:$$\frac{c_{2} - c_{1}}{2}$$posterior domain size given by:$$\frac{c_{2} - c_{1}}{L}$$and anterior domain size given by:$$1 - \frac{c_{2} - c_{1}}{L}$$where L is the length of the profile.

PAR-2 domain size change for each embryo was calculated as the ratio of domain size taken from images before and 5 min after PMA addition. Segregation efficiency into the anterior was scored by relative anterior domain size, with smaller anterior domains defined as more efficient segregation.

### Image Analysis -- Total Membrane Signal Change {#sec4.5.13}

To estimate total membrane signal in PAR-6 and PKC-3 rescue experiments straightened profiles were projected in x to give a cross-section profile spanning background, crossing the membrane and into the cytoplasm for the full circumference. Cross-section profiles were then normalized with background = 0 and cytoplasm = 1. To get the most accurate estimate of isolated membrane signal, we generated a mean cross-section for embryos with no detectable membrane signal from *par-3* and *par-6* RNAi embryos to define the shape of the outside to inside fluorescence step. The shape of this curve was extremely consistent allowing a mean profile to be generated, which could then be subtracted from individual embryo cross-section profiles with the sum of the difference taken as membrane signal.

For PAR-2 retention in C1B-induced PKC-3 membrane-targeting experiments, a cytoplasm-normalized 4-pixel wide stripe encompassing the cell membrane was taken from images before and 5 min after PMA addition to generate profiles. PAR-2 retention was defined as the ratio of total membrane signal before and after PMA addition.

### Statistics {#sec4.5.14}

For all assays, significance was assessed using an unpaired, two-tail Student's T test unless otherwise noted with the following criteria: ^∗^p\<0.05, ^∗∗^p\<0.01, ^∗∗∗^p\<0.001, ^∗∗∗∗^p\<0.0001. Data are presented as mean values plus all data points or mean ± 95% confidence interval (CI), in which case (N) is indicated.

### Data and Software Availability {#sec4.5.15}

Sequence data for *pkc-3(ne4246)* has been submitted to Wormbase (WB Gene: *pkc-3*).
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Document S1. Figures S1--S7Movie S1. Loss of PKC-3 Kinase Activity Leads to Symmetric Division in *C. elegans* Zygote, Related to Figure 10:00--0:05: CRT90-treated zygotes divide symmetrically*. perm-1*(*RNAi*) embryos are treated with DMSO (left) and CRT90 (10 μM, right) for ∼5 min prior to imaging. Acquisition of midplane DIC images starts at early establishment phase, and frames are captured every 20 s. Elapsed time, 21 min 20 s. Scale bar, 10 μm.0:05--0:09: *pkc-3*(*ts*) zygotes divide symmetrically*.* Wild-type (left) and *pkc-3*(*ts*) (middle) zygotes are imaged at the restrictive temperature of 25°C. PKC-3-depleted *pkc-3*(*RNAi*) (right panel) is imaged at room temperature (∼19°C). Acquisition of midplane DIC images starts at early establishment phase, and frames are captured every 20 s. Elapsed time, 14 min 40 s. Scale bar, 10 μm.Movie S2. Acute PKC-3 Inhibition Leads to Overlap of PAR-6/PKC-3 and PAR-2 in the *C. elegans* Zygote, Related to Figure 2*perm-1*(*RNAi*) embryos expressing either GFP::PKC-3 (0:00--0:07, elapsed time 23 min 00 s) or PAR-6::GFP (0:07--0:14, elapsed time 25 min 40 s) (top) and mCherry::PAR-2 (bottom) are treated with DMSO (left) or CRT-90 (10 μM, right) for ∼5 min prior to imaging. Acquisition of midplane fluorescent images begins at early establishment phase, and frames are captured every 20 s. Note that upon acute inhibition of PKC-3, PAR-6 and PKC-3 remain present at the membrane despite invasion of the anterior domain by PAR-2. Though both PAR-6 and PKC-3 are slightly asymmetric during the establishment phase, they become fully uniform, co-localized with PAR-2 throughout the embryo by maintenance phase. Scale bar, 10 μm.Movie S3. PKC-3 Acute Inhibition Partially Rescues PKC-3 Membrane Loading in Absence of PAR-3, Related to Figure 3*perm-1*/*par-3* (*RNAi*) embryo expressing GFP::PKC-3 is treated with CRT90 (10 μM) during image acquisition to illustrate the timescale of rescue. PKC-3 is visible within minutes of CRT90 treatment. Acquisition of midplane fluorescent images begins at early establishment phase, and frames are captured every 20 s. Elapsed time, 20 min. Scale bar, 10 μm.Movie S4. Acute PKC-3 Inhibition Can Rescue PKC-3 Membrane Loading in the Absence of PAR-3, but Not CDC-42 and PAR-6, Related to Figure 3*perm-1*/*par-3* (*RNAi*) (top), *perm-1*/*par-6* (*RNAi*) (middle), and *perm-1*/*cdc-42* (*RNAi*) (bottom) embryos expressing GFP::PKC-3 are treated with DMSO (left) and CRT90 (10 μM, right) for ∼5 min prior to imaging. Note that PKC-3 localization at the membrane is lost, from establishment phase in *par-6* (*RNAi*) and from maintenance phase in *cdc-42* (*RNAi*), neither of which is rescued by CRT90. Acquisition of midplane fluorescent images begins at early establishment phase, and frames are captured every 20 s. Elapsed time, 16 min. Scale bar, 10 μm.Movie S5. Polarization Is Associated with aPAR Clusters, Related to Figure 40:00--0:04: PAR-3 and PAR-6 form clustered assemblies that are efficiently transported by anterior-directed cortical flows. Wild-type embryos expressing PAR-3::GFP (top) or PAR-6::GFP (bottom) are imaged by pseudo-TIRF microscopy every 5 s. Acquisition of cortical fluorescent images begins at the onset of anterior-directed cortical flow. Note robust advection of PAR-3 and PAR-6 clusters (yellow circle, and surrounding clusters). Also, unlike PAR-3, there appears to be a diffuse PAR-6 population, which lags behind PAR-6 clusters. Elapsed time, 7 min. Scale bar, 10 μm.0:04--0:08: PAR-3 CR1 oligomerization domain is required for efficient transport by cortical flows. Embryos express either PAR-3(WT)::GFP (top) or PAR-3ΔCR1::GFP (bottom) together with PH-GBP, which tethers them to the membrane. Embryos are imaged by pseudo-TIRF microscopy every 5 s. Acquisition of cortical fluorescent images begins at the onset of anterior-directed cortical flow. Note that whereas PAR-3(WT) proteins are segregated to the anterior (top), oligomerization-deficient PAR-3 (PAR-3ΔCR1), even tethered to the membrane, is not, remaining mostly uniform at the cortex throughout the division. Elapsed time, 25 min 00 s. Scale bar, 10 μm.Movie S6. PKC-3 Membrane-Targeting Assay for Assessing PKC-3 Activity *In Vivo*, Related to Figure 6Wild-type embryos expressing mCherry::PAR-2 (right) and either GFP::C1B (top left) or GFP::C1B::PKC-3 (bottom left). C1B constructs are targeted to the membrane uniformly upon addition of PMA (100 μM, left). Whereas targeting C1B alone to the membrane has little effect on PAR-2 domain size (top right), uniform membrane localization of C1B::PKC-3 leads to significant shrinkage of the PAR-2 domain (bottom right). Note that PAR-2 is not fully removed compared with *par-3*(*RNAi*) in [Movie S7](#mmc8){ref-type="supplementary-material"}. Acquisition of midplane fluorescent images begins at late establishment phase (roughly when pronuclei meet), and frames are captured every 15 s. Elapsed time, 9 min 00 s. Scale bar, 10 μm.Movie S7. PKC-3 Membrane-Targeting Assay Reveals Opposing Roles for PAR-3 and CDC-42 in Regulating PKC-3 Activity, Related to Figure 6Embryos expressing mCherry::PAR-2 (right) and GFP::C1B::PKC-3 (left) are depleted of PAR-6 (*par-6* (*RNAi*), top), PAR-3 (*par-3* (*RNAi*), middle), and CDC-42 (*cdc-42* (*RNAi*), bottom). Upon PMA (100 μM) addition, C1B::PKC-3 is targeted uniformly to the membrane. Whereas this does not affect PAR-2 uniform distribution at the membrane in *par-6* (*RNAi*) and *cdc-42* (*RNAi*), it triggers a complete and rapid removal of PAR-2 in the absence of PAR-3 (bottom right). Acquisition of midplane fluorescent images begins at late establishment phase (roughly when pronuclei meet), and frames are captured every 15 s. Elapsed time, 8 min 45 s. Scale bar, 10 μm.Document S2. Article plus Supplemental Information
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